Skip to main content
SpringerLink
Log in

Stem Cell Transplantation for Marrow Failure

  • Chapter
Book cover Hematopoietic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

  • 1299 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ehrlich P. Ueber einen Fall von Anämie mit Bemerkungen über regenerative Veränderungen des Knochenmarks. Charité-Annalen 1888;13:300–309.

    Google Scholar 

  2. Marsh JC, Ball SE, Darbyshire P, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol. 2003;123:782–801.

    PubMed  CAS  Google Scholar 

  3. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–2519.

    PubMed  CAS  Google Scholar 

  4. Young NS. Acquired aplastic anemia. Ann Intern Med. 2002;136:534–546.

    PubMed  Google Scholar 

  5. Issaragrisil S, Kaufman DW, Anderson T, et al. The epidemiology of aplastic anemia in Thailand. Blood. 2006;107:1299–1307.

    PubMed  CAS  Google Scholar 

  6. Shimamura A. Inherited bone marrow failure syndromes: molecular features. Hematology Am Soc Hematol Educ Program. 2006:63–71.

    Google Scholar 

  7. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37:69–80.

    PubMed  CAS  Google Scholar 

  8. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol. 2000;37:30–42.

    PubMed  CAS  Google Scholar 

  9. Margolis DA, Casper JT. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. Semin Hematol. 2000;37:43–55.

    PubMed  CAS  Google Scholar 

  10. Marsh J. Making therapeutic decisions in adults with aplastic anemia. Hematology Am Soc Hematol Educ Program. 2006:78–85.

    Google Scholar 

  11. Osgood EE, Riddle MC, Mathews TJ. Aplastic anemia treated with daily transfusions and intravenous marrow; case report. American Journal of Medicine. 1939;13:357–367.

    Google Scholar 

  12. Morrison M, Samwick AA. Intramedullary (sternal) transfusion of human bone marrow. JAMA. 1940;115:1708–1711.

    Google Scholar 

  13. Robins MM, Noyes WD. Aplastic anemia treated with bone-marrow infusion from identical twin. New England Journal of Medicine. 1961;265:974–979.

    PubMed  CAS  Google Scholar 

  14. Thomas ED, Storb R, Fefer A, et al. Aplastic anaemia treated by marrow transplantation. Lancet. 1972;1:284–289.

    PubMed  CAS  Google Scholar 

  15. Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48:63–70.

    PubMed  CAS  Google Scholar 

  16. Mathe G, Amiel JL, Schwarzenberg L, et al. Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J. 1970;2:131–136.

    PubMed  CAS  Google Scholar 

  17. Appelbaum FR, Fefer A, Cheever MA, et al. Treatment of aplastic anemia by bone marrow transplantation in identical twins. Blood. 1980;55:1033–1039.

    PubMed  CAS  Google Scholar 

  18. Speck B, Kissling M. Studies on bone marrow transplantation in experimental 32P-induced aplastic anemia after conditioning with antilymphocyte serum. Acta Haematol. 1973;50:193–199.

    PubMed  CAS  Google Scholar 

  19. Champlin RE, Feig SA, Sparkes RS, Galen RP. Bone marrow transplantation from identical twins in the treatment of aplastic anaemia: implication for the pathogenesis of the disease. Br J Haematol. 1984;56:455–463.

    PubMed  CAS  Google Scholar 

  20. Anasetti C, Doney KC, Storb R, et al. Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty “untransfused” patients. Ann Intern Med. 1986;104:461–466.

    PubMed  CAS  Google Scholar 

  21. Kiem HP, McDonald GB, Myerson D, et al. Marrow transplantation for hepatitis-associated aplastic anemia: a follow-up of long-term survivors. Biol Blood Marrow Transplant. 1996;2:93–99.

    PubMed  CAS  Google Scholar 

  22. Eapen M, Ramsay NK, Mertens AC, Robison LL, DeFor T, Davies SM. Late outcomes after bone marrow transplant for aplastic anaemia. Br J Haematol. 2000;111:754–760.

    PubMed  CAS  Google Scholar 

  23. Kahl C, Leisenring W, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol. 2005;130:747–751.

    PubMed  CAS  Google Scholar 

  24. Deeg HJ, Socie G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386–392.

    PubMed  CAS  Google Scholar 

  25. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991;324:1297–1304.

    PubMed  CAS  Google Scholar 

  26. Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol. 2000;37: 56–68.

    PubMed  CAS  Google Scholar 

  27. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236–1242.

    PubMed  CAS  Google Scholar 

  28. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. Jama. 2003;289:1130–1135.

    PubMed  CAS  Google Scholar 

  29. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006;133:622–627.

    PubMed  CAS  Google Scholar 

  30. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37:91–101.

    PubMed  CAS  Google Scholar 

  31. Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med. 1993;329:1152–1157.

    PubMed  CAS  Google Scholar 

  32. Territo MC. Autologous bone marrow repopulation following high dose cyclophos-phamide and allogeneic marrow transplantation in aplastic anaemia. Br J Haematol. 1977;36:305–312.

    PubMed  CAS  Google Scholar 

  33. Brodsky RA, Sensenbrenner LL, Smith BD, et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med. 2001;135:477–483.

    PubMed  CAS  Google Scholar 

  34. Tisdale JF, Dunn DE, Geller N, et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet. 2000;356:1554–1559.

    PubMed  CAS  Google Scholar 

  35. Tisdale JF, Maciejewski JP, Nunez O, Rosenfeld SJ, Young NS. Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophos-phamide (Cy): follow-up of a randomized trial. Blood. 2002;100:4668–4670.

    PubMed  CAS  Google Scholar 

  36. Storb R, Longton G, Anasetti C, et al. Changing trends in marrow transplantation for aplastic anemia. Bone Marrow Transplant. 1992;10 Suppl 1:45–52.

    PubMed  Google Scholar 

  37. McCann SR, Bacigalupo A, Gluckman E, et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant. 1994;13:233–237.

    PubMed  CAS  Google Scholar 

  38. Gale RP, Ho W, Feig S, et al. Prevention of graft rejection following bone marrow transplantation. Blood. 1981;57:9–12.

    PubMed  CAS  Google Scholar 

  39. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73:606–613.

    PubMed  CAS  Google Scholar 

  40. Gluckman E, Horowitz MM, Champlin RE, et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood. 1992;79:269–275.

    PubMed  CAS  Google Scholar 

  41. Storb R, Prentice RL, Thomas ED, et al. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol. 1983;55:573–585.

    PubMed  CAS  Google Scholar 

  42. Deeg HJ, Self S, Storb R, et al. Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. Blood. 1986;68:1363–1368.

    PubMed  CAS  Google Scholar 

  43. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461–466.

    PubMed  CAS  Google Scholar 

  44. Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004;103:2490–2497.

    PubMed  CAS  Google Scholar 

  45. Wagner JL, Deeg HJ, Seidel K, et al. Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. Transplantation. 1996;61:54–61.

    PubMed  CAS  Google Scholar 

  46. Deeg HJ, O'Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108:1485–1491.

    PubMed  CAS  Google Scholar 

  47. Storb R, Thomas ED, Weiden PL, et al. Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. Blood. 1976;48:817–841.

    PubMed  CAS  Google Scholar 

  48. Storb R, Weiden PL, Sullivan KM, et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood. 1987;70:116–121.

    PubMed  CAS  Google Scholar 

  49. Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithy-mocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941–949.

    PubMed  CAS  Google Scholar 

  50. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36:947–950.

    PubMed  CAS  Google Scholar 

  51. Maury S, Anderlini P, Viollier R, et al. Overcoming the negative impact of age using fludarabine-based conditioning regimens for HLA-identical sibling HSCT in patients withsevere aplastic anemia (SAA): A Study from the EBMT-SAA Working Party. Blood (ASH Annual Meeting Abstracts). 2006;108:3007.

    Google Scholar 

  52. Gupta V, Ball SE, Sage D, et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant. 2005;35:467–471.

    PubMed  CAS  Google Scholar 

  53. Hinterberger W, Rowlings PA, Hinterberger-Fischer M, et al. Results of transplanting bone marrow from genetically identical twins into patients with aplastic anemia. Ann Intern Med. 1997;126:116–122.

    PubMed  CAS  Google Scholar 

  54. Hows JM, Palmer S, Gordon-Smith EC. Use of cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anemia. Transplantation. 1982;33:382– 386.

    PubMed  CAS  Google Scholar 

  55. Hows J, Palmer S, Gordon-Smith EC. Cyclosporine and graft failure following bone marrow transplantation for severe aplastic anaemia. Br J Haematol. 1985;60: 611–617.

    PubMed  CAS  Google Scholar 

  56. May WS, Sensenbrenner LL, Burns WH, et al. BMT for severe aplastic anemia using cyclosporine. Bone Marrow Transplant. 1993;11:459–464.

    PubMed  CAS  Google Scholar 

  57. Stucki A, Leisenring W, Sandmaier BM, Sanders J, Anasetti C, Storb R. Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). Blood. 1998;92:2742–2749.

    PubMed  CAS  Google Scholar 

  58. Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 1986;68:119–125.

    PubMed  CAS  Google Scholar 

  59. Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 1999;5:243–252.

    PubMed  CAS  Google Scholar 

  60. Herrera-Garza J, Jaime-Perez J, Montemayor J, Ibarra-Peart R, Gomez-Almaguer D. High-dose peripheral blood stem cell transplant for multitransfused severe aplastic anaemia patients without antithymocyte globulin in the conditioning regimen. Bone Marrow Transplant. 1999;24:845–848.

    PubMed  CAS  Google Scholar 

  61. Schwinger W, Urban C, Lackner H, et al. Unrelated peripheral blood stem cell transplantation with ‘megadoses’ of purified CD34+ cells in three children with refractory severe aplastic anemia. Bone Marrow Transplant. 2000;25: 513–517.

    PubMed  CAS  Google Scholar 

  62. Schrezenmeier H, Bredeson C, Bruno B, et al. Comparison of allogeneic bone marrow and peripheral blood stem cell transplantation for aplastic anemia: collaborative study of European Blood and Marrow Transplant Group (EBMT) and International Bone Marrow Transplant Registry (IBMTR). Blood (ASH Annual Meeting Abstracts). 2003;102:267a.

    Google Scholar 

  63. Motwani J, Lawson SE, Darbyshire PJ. Successful HSCT using nonradiotherapy-based conditioning regimens and alternative donors in patients with Fanconi anaemia experience in a single UK centre. Bone Marrow Transplant. 2005;36:405–410.

    PubMed  CAS  Google Scholar 

  64. Mao P, Zhu Z, Wang H, et al. Sustained and stable hematopoietic donor-recipient mixed chimerism after unrelated cord blood transplantation for adult patients with severe aplastic anemia. Eur J Haematol. 2005;75:430–435.

    PubMed  CAS  Google Scholar 

  65. Gluckman E. Current status of bone marrow transplantation for severe aplastic anemia: a preliminary report from the International Bone Marrow Transplant Registry. Transplant Proc. 1987;19:2597–2599.

    PubMed  CAS  Google Scholar 

  66. Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med. 1997;126: 107–115.

    PubMed  CAS  Google Scholar 

  67. Marsh JC, Hows JM, Bryett KA, Al-Hashimi S, Fairhead SM, Gordon-Smith EC. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987;70:1046–1052.

    PubMed  CAS  Google Scholar 

  68. Tichelli A, Socie G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med. 1999;130:193–201.

    PubMed  CAS  Google Scholar 

  69. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93:2191–2195.

    PubMed  CAS  Google Scholar 

  70. Giampietro PF, Verlander PC, Davis JG, Auerbach AD. Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry Study. Am J Med Genet. 1997;68:58–61.

    PubMed  CAS  Google Scholar 

  71. Tischkowitz MD, Hodgson SV. Fanconi anaemia. J Med Genet. 2003;40:1–10.

    PubMed  CAS  Google Scholar 

  72. Casado JA, Callen E, Jacome A, et al. A comprehensive strategy for the subtyping of Fanconi Anemia patients: conclusions from the Spanish Fanconi Anemia research network. J Med Genet. 2006.

    Google Scholar 

  73. Wagner JE, Eapen M, Macmillan ML, et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood. 2006.

    Google Scholar 

  74. Guardiola P, Socie G, Li X, et al. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. Blood. 2004;103:73–77.

    PubMed  CAS  Google Scholar 

  75. Gluckman E, Auerbach A, Ash RC, et al. Allogeneic bone marrow transplants for Fanconi anemia. A preliminary report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1992;10 Suppl 1:53–57.

    PubMed  Google Scholar 

  76. Gluckman E, Auerbach AD, Horowitz MM, et al. Bone marrow transplantation for Fanconi anemia. Blood. 1995;86:2856–2862.

    PubMed  CAS  Google Scholar 

  77. Camitta BM, Thomas ED, Nathan DG, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504–514.

    PubMed  CAS  Google Scholar 

  78. Gluckman E, Socie G, Devergie A, Bourdeau-Esperou H, Traineau R, Cosset JM. Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: long-term follow-up. Blood. 1991;78:2451–2455.

    PubMed  CAS  Google Scholar 

  79. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–1258.

    PubMed  CAS  Google Scholar 

  80. Peffault de Latour R, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria (PNH): long-term epidemiological study. Blood (ASH Annual Meeting Abstracts). 2006;108:973.

    Google Scholar 

  81. Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100:3897–3902.

    PubMed  CAS  Google Scholar 

  82. Nakao S, Sugimori C, Yamazaki H. Clinical significance of a small population of paroxysmal nocturnal hemoglobinuria-type cells in the management of bone marrow failure. Int J Hematol. 2006;84:118–122.

    PubMed  Google Scholar 

  83. Storb R, Evans RS, Thomas ED, et al. Paroxysmal nocturnal haemoglobinuria and refractory marrow failure treated by marrow transplantation. Br J Haematol. 1973;24:743–750.

    PubMed  CAS  Google Scholar 

  84. Hershko C, Gale RP, Ho WG, Cline MJ. Cure of aplastic anaemia in paroxysmal nocturnal haemoglobinuria by marrow transfusion from identical twin: Failure of peripheral-leucocyte transfusion to correct marrow aplasia. Lancet. 1979;1:945–947.

    PubMed  CAS  Google Scholar 

  85. Szer J, Deeg HJ, Witherspoon RP, et al. Long-term survival after marrow transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia. Ann Intern Med. 1984;101:193–195.

    PubMed  CAS  Google Scholar 

  86. Antin JH, Ginsburg D, Smith BR, Nathan DG, Orkin SH, Rappeport JM. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood. 1985;66:1247–1250.

    PubMed  CAS  Google Scholar 

  87. Hegenbart U, Niederwieser D, Forman S, et al. Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant. 2003;9:689–697.

    PubMed  CAS  Google Scholar 

  88. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with aplastic anemia given first line transplantion or immunosuppression in the last decade: a rReport from European Group for Blood and Marrow Transplantation (EBMT). Blood (ASH Annual Meeting Abstracts). 2006;108:52.

    Google Scholar 

  89. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med. 1983;308: 302–307.

    PubMed  CAS  Google Scholar 

  90. Marsh JC. Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemia. Semin Hematol. 2000;37:81–90.

    PubMed  CAS  Google Scholar 

  91. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol. 2006;133:606–611.

    PubMed  CAS  Google Scholar 

  92. Passweg JR, Perez WS, Eapen M, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant. 2006;37:641–649.

    PubMed  CAS  Google Scholar 

  93. Kennedy-Nasser AA, Leung KS, Mahajan A, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006;12:1277–1284.

    PubMed  Google Scholar 

  94. Maury S, Balere-Appert M-L, Chir Z, et al. Unrelated allogeneic stem cell transplantation forsevere acquired aplastic anemia: has outcome improved? Blood (ASH Annual Meeting Abstracts). 2006;108:3105.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

    Philippe Armand MD, PhD & Joseph H. Antin MD

Authors
  1. Philippe Armand MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph H. Antin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, DFCI D1B30, Boston, MA, 02115, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Armand, P., Antin, J.H. (2008). Stem Cell Transplantation for Marrow Failure. In: Soiffer, R.J. (eds) Hematopoietic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-438-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-438-4_10

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-05-3

  • Online ISBN: 978-1-59745-438-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation